GVK BIO completes repurposing efforts to identify novel indications for Takeda

Indian discovery R&D organization GVK Biosciences says it has successfully completed in-silico based alternative indications of shelved compounds for Japanese pharma major Takeda Pharmaceutical (TYO: 4502) using GVK BIO’s proprietary Drug Repurposing platform.

Taking the project to the next level, GVK BIO and Takeda have jointly agreed to evaluate the preclinical proof-of-concept for certain indications of selected therapeutic compounds to develop novel indications for the previously failed compounds.

Having worked for over a decade with global majors in the Pharmaceutical industry, GVK BIO has leveraged its experience and expertise in Drug Discovery and has developed a unique Drug Repurposing platform called GRIP. It is a combination of repurposing database, eight different algorithms, analytics tools and a visualization engine.